Mortality as an endpoint in atrial fibrillation

Daniel M. Beyerbach, Douglas P. Zipes

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The aim of this study was to evaluate the use of mortality as an appropriate endpoint in studies of atrial fibrillation. Almost none of the atrial fibrillation trials has shown a significant difference in mortality among the various treatment arms because the studies are small, and many patient-years are required to show significant differences. Differences can be found when mortality is used as part of a combined endpoint and in meta-analyses of atrial fibrillation trials. Some trials of atrial fibrillation in the setting of conditions predisposing to high mortality, such as heart failure, postmyocardial infarction, and perioperative state for surgical procedures, can have mortality differences. Nevertheless, mortality has a role in validating the safety of new therapies and can be used as a measure of the impact and prognostic significance of atrial fibrillation in various disease settings.

Original languageEnglish (US)
Pages (from-to)8-19
Number of pages12
JournalHeart Rhythm
Volume1
Issue number2 SUPPL.
DOIs
StatePublished - Jul 2004

Fingerprint

Atrial Fibrillation
Mortality
Infarction
Meta-Analysis
Heart Failure
Safety
Therapeutics

Keywords

  • Anticoagulation
  • Epidemiology
  • Stroke
  • Sudden death
  • Ventricular arrhythmia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Mortality as an endpoint in atrial fibrillation. / Beyerbach, Daniel M.; Zipes, Douglas P.

In: Heart Rhythm, Vol. 1, No. 2 SUPPL., 07.2004, p. 8-19.

Research output: Contribution to journalArticle

Beyerbach, DM & Zipes, DP 2004, 'Mortality as an endpoint in atrial fibrillation', Heart Rhythm, vol. 1, no. 2 SUPPL., pp. 8-19. https://doi.org/10.1016/j.hrthm.2004.04.018
Beyerbach, Daniel M. ; Zipes, Douglas P. / Mortality as an endpoint in atrial fibrillation. In: Heart Rhythm. 2004 ; Vol. 1, No. 2 SUPPL. pp. 8-19.
@article{8c564366b07a41c2bf90fa0cb688b49a,
title = "Mortality as an endpoint in atrial fibrillation",
abstract = "The aim of this study was to evaluate the use of mortality as an appropriate endpoint in studies of atrial fibrillation. Almost none of the atrial fibrillation trials has shown a significant difference in mortality among the various treatment arms because the studies are small, and many patient-years are required to show significant differences. Differences can be found when mortality is used as part of a combined endpoint and in meta-analyses of atrial fibrillation trials. Some trials of atrial fibrillation in the setting of conditions predisposing to high mortality, such as heart failure, postmyocardial infarction, and perioperative state for surgical procedures, can have mortality differences. Nevertheless, mortality has a role in validating the safety of new therapies and can be used as a measure of the impact and prognostic significance of atrial fibrillation in various disease settings.",
keywords = "Anticoagulation, Epidemiology, Stroke, Sudden death, Ventricular arrhythmia",
author = "Beyerbach, {Daniel M.} and Zipes, {Douglas P.}",
year = "2004",
month = "7",
doi = "10.1016/j.hrthm.2004.04.018",
language = "English (US)",
volume = "1",
pages = "8--19",
journal = "Heart Rhythm",
issn = "1547-5271",
publisher = "Elsevier",
number = "2 SUPPL.",

}

TY - JOUR

T1 - Mortality as an endpoint in atrial fibrillation

AU - Beyerbach, Daniel M.

AU - Zipes, Douglas P.

PY - 2004/7

Y1 - 2004/7

N2 - The aim of this study was to evaluate the use of mortality as an appropriate endpoint in studies of atrial fibrillation. Almost none of the atrial fibrillation trials has shown a significant difference in mortality among the various treatment arms because the studies are small, and many patient-years are required to show significant differences. Differences can be found when mortality is used as part of a combined endpoint and in meta-analyses of atrial fibrillation trials. Some trials of atrial fibrillation in the setting of conditions predisposing to high mortality, such as heart failure, postmyocardial infarction, and perioperative state for surgical procedures, can have mortality differences. Nevertheless, mortality has a role in validating the safety of new therapies and can be used as a measure of the impact and prognostic significance of atrial fibrillation in various disease settings.

AB - The aim of this study was to evaluate the use of mortality as an appropriate endpoint in studies of atrial fibrillation. Almost none of the atrial fibrillation trials has shown a significant difference in mortality among the various treatment arms because the studies are small, and many patient-years are required to show significant differences. Differences can be found when mortality is used as part of a combined endpoint and in meta-analyses of atrial fibrillation trials. Some trials of atrial fibrillation in the setting of conditions predisposing to high mortality, such as heart failure, postmyocardial infarction, and perioperative state for surgical procedures, can have mortality differences. Nevertheless, mortality has a role in validating the safety of new therapies and can be used as a measure of the impact and prognostic significance of atrial fibrillation in various disease settings.

KW - Anticoagulation

KW - Epidemiology

KW - Stroke

KW - Sudden death

KW - Ventricular arrhythmia

UR - http://www.scopus.com/inward/record.url?scp=3042733004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042733004&partnerID=8YFLogxK

U2 - 10.1016/j.hrthm.2004.04.018

DO - 10.1016/j.hrthm.2004.04.018

M3 - Article

C2 - 15851134

AN - SCOPUS:3042733004

VL - 1

SP - 8

EP - 19

JO - Heart Rhythm

JF - Heart Rhythm

SN - 1547-5271

IS - 2 SUPPL.

ER -